Company intelligence / Profile preview

The Collaborators

North Carolina, United Statesthecollaborators.com ↗

Ownership: Private
Development stage: Other

Overview

Collaborations Pharmaceuticals uses artificial intelligence and machine learning platforms to discover and develop therapeutics for rare, neglected, and unmet medical needs. The company has advanced at least one treatment to the manufacturing/IND-enabling toxicology stage as of 2025. They have a strong track record in securing NIH and DOD funding.

Therapeutic areas: Rare DiseasesInfectious Diseases
Modalities: Small moleculeBiologicArtificial intelligence-driven drug design tools
Industry: Biotech

Partnerships

NIH (funding partner)DOD (funding partner)Various academic scientists, rare disease foundations, other companies via licensing or strategic partnerships

Beyond the preview

Go deeper on The Collaborators.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Collaborators.

Explore the full profile